Search Medical Condition
Please enter condition
Please choose location from dropdown

Grenoble Cedex, France Clinical Trials

A listing of Grenoble Cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (432) clinical trials

EXpanded CELL ENdocardiac Transplantation (EXCELLENT)

The main purpose of this phase I/IIB is to evaluate the safety, the tolerance and the first efficacy trends of intracardiac injection of ProtheraCytes (autologous PB-CD34+ Stem Cells after automated ex-vivo expansion with the StemXpand machine) in patients with a De Novo acute myocardial infarction and decreased ejection fraction. ProtheraCytes ...

Phase

0.0 miles

Learn More »

Study to Evaluate the Efficacy Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients

This will be a double-blind, randomised, placebo-controlled parallel-arm phase II proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing both end-of-dose wearing off and Levodopa-Induced Dyskinesia (LID)

Phase

0.0 miles

Learn More »

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Study AG120-C-009 is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (ivosidenib) + azacitidine vs placebo + azacitidine in adult subjects with previously untreated IDH1m AML who are considered appropriate candidates for non-intensive therapy. The primary endpoint is Overall Survival ...

Phase

0.0 miles

Learn More »

Safety and Efficacy of 2 Treatment Regimens of Aztreonam for Inhalation Solution in Children With Cystic Fibrosis and New Onset Pseudomonas Aeruginosa Infection

The primary objective of this study is to evaluate the safety and efficacy of a 14-day course versus a 28-day course of aztreonam for inhalation solution (AZLI) in participants with new onset Pseudomonas aeruginosa respiratory tract infection.

Phase

0.0 miles

Learn More »

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

This is a double-blind, randomized-withdrawal, placebo-controlled study in kidney transplant patients with AMR to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care (IVIG).

Phase

0.0 miles

Learn More »

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). There is no approved treatment for patients with C3G. This is a randomized, double blind, placebo controlled ...

Phase

0.0 miles

Learn More »

Evaluation of EYS606 in Patients With Non-infectious Posterior Intermediate or Panuveitis

The maximum study duration per patient is 27 Weeks (including an up to 3 week screening period + 24 weeks follow-up after treatment). The study is conducted in 2 parts. Part 1 is a dose escalation phase which will investigate 3 pEYS606 doses levels (lower, intermediate and higher dose) over ...

Phase

0.0 miles

Learn More »

Firazyr Patient Registry (Icatibant Outcome Survey - IOS)

The Icatibant Outcome Survey (IOS) is a multicenter, prospective, observational study for participants treated with Firazyr (icatibant) and/or Cinryze (C1 inhibitor [human]) in countries where it is currently approved. The entry of participants in the Icatibant Outcome Survey (IOS) is at the discretion of the physician and the participant and ...

Phase N/A

0.0 miles

Learn More »

Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure

Sleep Apnea (SA) is a disorder that causes pauses in breathing during sleep that expose the heart to oxygen deprivation. It is common in patients with heart failure (HF) where it is associated with increased risk of hospitalizations and death. It is not known however whether treating SA reduces these ...

Phase

0.0 miles

Learn More »

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

The study will capture post-marketing safety data on patients treated with eculizumab. Additionally, the study will collect information on the progression of disease in all patients.

Phase N/A

0.0 miles

Learn More »